- Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1 (fiercepharma.com)
On the flip side, AstraZeneca, GSK and J&J stock prices contracted… The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects of China's stock market meltdown and saw values rise 23%. But, of course, averages come from the highs and the lows and some players have actually seen share price declines during this bull market.
